title: Cancer targeted metallic nanoparticle: targeting overview, recent advancement and toxicity concern.
abstract: The targeted delivery of theranostic agents to the cancer cells is one of the major challenges and an active field of research in the development of cancer chemotherapeutic approaches. Theranostic metallic nanoparticles (TMNPs) have garnered increasing attention in recent years as a novel tool for theranostic application such as imaging, diagnosis, and therapeutic delivery of active agents to tumour specific cells. This paper attempts to unveil the multidimensional theranostic aspects of multifunctional metallic nanoparticles (MNPs)including passive and active targeting (HER2, Folate, Angiogenesis etc.) as well as the RES escaping approach. Special attention is given to the theranostic application of MNPs in oncology. Patents issued by the US office in this nanotechnological arena are also included emphasising the importance of MNPs in current cancer treatment/imaging research scenario. Keeping in mind the blooming research in clinical application directed nanotechnology; toxicity concerns related with MNPs are. also discussed, in element.
authors.affiliation: Nanoformulation Research Lab., Jamia Hamdard (Hamdard University), New Delhi-62, India.
authors.forename: Sohail
authors.initials: S
authors.lastname: Akhter
authors.forename: Zaki
authors.initials: Z
authors.lastname: Ahmad
authors.forename: Anjali
authors.initials: A
authors.lastname: Singh
authors.forename: Iqbal
authors.initials: I
authors.lastname: Ahmad
authors.forename: Mahfoozur
authors.initials: M
authors.lastname: Rahman
authors.forename: Mohammad
authors.initials: M
authors.lastname: Anwar
authors.forename: Gaurav Kumar
authors.initials: GK
authors.lastname: Jain
authors.forename: Farhan Jalees
authors.initials: FJ
authors.lastname: Ahmad
authors.forename: Roop Krishen
authors.initials: RK
authors.lastname: Khar
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D016503:Drug Delivery Systems / Q000379:methods; D058972:Folic Acid Transporters; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology; D006801:Humans; D053768:Metal Nanoparticles / Q000009:adverse effects* / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D010330:Patents as Topic; D045663:Quantum Dots; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D018675:Toxicity Tests
chemical_list: D000970:Antineoplastic Agents; D058972:Folic Acid Transporters; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human